From GlobeNewswire: 2025-05-13 16:45:00

Silexion Therapeutics Corp reported financial results for Q1 2025, highlighting progress in developing RNAi therapies for KRAS-driven cancers. Positive data from SIL204 program showed significant anti-tumor and anti-metastatic activity in orthotopic models. The company also announced a dual-route development strategy for SIL204 to address primary tumors and metastases. Strategic collaborations and financial strengthening were also key developments.

In Q1 2025, Silexion’s cash and cash equivalents increased to $6.2 million, up from $1.2 million in December 2024. Operating expenses totaled $1.7 million, with research and development expenses decreasing while general and administrative expenses increased. Financial expenses decreased to $0.1 million. The net loss for the quarter was $1.7 million, reflecting progress in the company’s development efforts.

Silexion Therapeutics is focused on developing innovative RNA interference therapies for solid tumors driven by KRAS mutations. Their first-generation product, LODER™, showed promise in a Phase 2 trial for non-resectable pancreatic cancer. The next-generation siRNA candidate, SIL204, targets a broader range of KRAS mutations. The company aims to improve outcomes for patients with challenging cancers.



Read more at GlobeNewswire:: Silexion Therapeutics Reports First Quarter 2025 Financial